Emergências e Terapia Intensiva
Outro estudo randomizado avaliou a eficácia e a qualidade de vida no tratamento somente com antibióticos da apendicite aguda não complicada.
13 Jul, 2021 | 11:16hA Randomized Clinical Trial Evaluating the Efficacy and Quality of Life of Antibiotic-only Treatment of Acute Uncomplicated Appendicitis: Results of the COMMA Trial – Annals of Surgery (link para o resumo – $ para o texto completo)
Relacionado: A Randomized trial comparing antibiotics with appendectomy for appendicitis E Antibiotics alone for uncomplicated appendicitis: Oral Moxifloxacin almost as good as intravenous Ertapenem + oral Levofloxacin E Observational study: 67.1% success rate with nonoperative management of children with uncomplicated appendicitis E Randomized Trial: Quality of Life and Patient Satisfaction at 7-Year Follow-up of Antibiotic Therapy vs. Appendectomy for Uncomplicated Acute Appendicitis E Meta-Analysis: Antibiotic Treatment vs. Appendectomy for Uncomplicated Acute Appendicitis in Adults and Children E Nonoperative treatment for nonperforated appendicitis in children: a systematic review and meta-analysis – Pediatric Surgery International
Comentário no Twitter
The debate continues!
Another RCT comparing antibiotics to surgery for uncomplicated appendicitis – COMMA trial from 🇮🇪
Recurrence within 1-year : 25% after AB
Superior quality of life at 3 and 12mo after surgery.https://t.co/Yv51qpxchb
— Ville Sallinen (@villesallinen) July 11, 2021
Revisão | Encefalopatias associadas a doenças infecciosas.
13 Jul, 2021 | 11:13hInfectious disease-associated encephalopathies – Critical Care
Comentário no Twitter
A Review published in Critical Care focuses on the pathophysiology of encephalopathies associated with sepsis, malaria, influenza, and COVID-19; emerging therapeutic strategies; and the role of neuroinflammation. https://t.co/991S4kAKJk
— BMC (@BioMedCentral) July 11, 2021
10 tópicos principais para reconhecimento, avaliação e tratamento da sepse materna.
13 Jul, 2021 | 11:12hEstudo randomizado | Comparação da cetamina nebulizada em 3 regimes de dose diferentes para o tratamento de condições dolorosas no departamento de emergência.
13 Jul, 2021 | 11:11hComparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind Clinical Trial – Annals of Emergency Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Nebulized Ketamine for pain in the ED? No way…Well- here you go-Comparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the ED. https://t.co/v3UT0Y0LdU #FOAMed #FOAMems #FOAMtox #FOAMcc #FOAMpharm
— Sergey Motov (@painfreeED) July 3, 2021
M-A | Mortalidade similar tanto com fluoroquinolonas quanto com macrolídeos no tratamento da pneumonia por Legionella.
13 Jul, 2021 | 11:08hAre Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis – Clinical Infectious Diseases (link para o resumo – $ para o texto completo)
[Preprint] Heparina para pacientes com Covid-19 moderada – “Em pacientes com Covid-19 moderada e D-dímero elevado, a terapia com heparina não reduziu significativamente o desfecho primário, mas reduziu as chances de morte em 28 dias de doença.”
12 Jul, 2021 | 11:41hHeparin for Moderately Ill Patients with Covid-19 – medRxiv
Relacionado: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. E [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. E [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
Comentário no Twitter (fio – clique para saber mais)
🚨Final results of the RAPID trial now pub'd @medrxivpreprint 🚨 RAPID was an open-label trial that randomly assigned hospitalized ward patients with COVID-19 and elevated D-dimer levels to therapeutic or prophylactic heparin. 🧵 1/10 https://t.co/oxiyXQAPeK pic.twitter.com/V2GtruEyM2
— Michelle Sholzberg (@sholzberg) July 9, 2021
Estudo randomizado | Outro estudo mostra que a azitromicina não melhora os desfechos em pacientes com Covid-19.
12 Jul, 2021 | 11:37hComentários: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases E Azithromycin: can its benefit be ruled out in mild COVID-19? – The Lancet Respiratory Medicine
Relacionado: M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19. E RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19 E RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 E E Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19 E Coalition Covid-19 Brazil – Randomized trial: hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19
Comentário no Twitter
In patients with mild-to-mod #COVID19 managed without hospital admission, azithromycin + SOC did not reduce the risk of subsequent hospital admission or death
Read the ATOMIC2 trial here https://t.co/QXJ7T08JZS, being presented at #ECCMID2021 by lead author Tim Hinks @HinksLab pic.twitter.com/ZDiPhuQqFB
— The Lancet Respiratory Medicine (@LancetRespirMed) July 9, 2021
Relatório oficial do American Thoracic Society Workshop | Entendendo o hospedeiro no tratamento da pneumonia.
12 Jul, 2021 | 11:26hEstudo randomizado | Outro estudo mostra a segurança do tratamento ambulatorial sem antibióticos na diverticulite aguda leve.
12 Jul, 2021 | 11:19hEfficacy and Safety of Non-Antibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-Label, Non-Inferiority Trial – Annals of Surgery (link para o resumo – $ para o texto completo)
Relacionado: State of the Art Review: Management of colonic diverticulitis E Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics: A Systematic Review and Meta-analysis – Diseases of the Colon & Rectum E Antibiotics Do Not Reduce Length of Hospital Stay for Uncomplicated Diverticulitis in a Pragmatic Double-Blind Randomized Trial – Clinical Gastroenterology and Hepatology E Randomized Trial: Antibiotic Avoidance Associated with Similar Long-term Outcomes in Uncomplicated Diverticulitis
Comentário no Twitter
Another (final?) nail in the coffin for antibiotics in uncomplicated diverticulitis? DINAMO study from Spain – Outpatient treatment with antibiotics versus symptomatic Tx.
No difference in hospitalization rate or revisits to ER.https://t.co/wOc3tBGfxr @AnnalsofSurgery
— Ville Sallinen (@villesallinen) July 9, 2021
M-A | Comparação de eficácia e segurança de vancomicina, linezolida, tedizolida e daptomicina no tratamento de pacientes com infecção suspeita ou comprovada de pele e partes moles.
9 Jul, 2021 | 15:47h
Comentário no Twitter
🆕💥 Network Meta-Analysis @InfectDis_Ther
20 RCTs N=7804
Comparative Efficacy& Safety of Vancomycin,Linezolid,Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven cSSTI
Linezolid was superior to vancomycin in improving clinical successhttps://t.co/qlZfXoWfaa pic.twitter.com/tO3sIoOMY4— Antibiotic Steward 🇵🇸💔Bassam Ghanem (@ABsteward) June 20, 2021